Efficacy of panitumumab in older patients with metastatic colorectal cancer: a retrospective analysis using the database of the Hellenic Oncology Research Group (HORG)

Impact of age and gender on the efficacy and safety of upfront therapy with panitumumab plus FOLFOX followed by panitumumab-based maintenance: a pre-specified subgroup analysis of the Valentino study

“…Specifically, the safety and efficacy outcome of elderly patients fit enough to receive combination chemotherapy plus biological agents is an issue of growing interest. [16][17][18] In this subgroup analysis of the Valentino study, no significant differences for efficacy in terms of PFS, OS, clinical benefit and response rate were observed between patients aged <70 or 70 years and the effect of the maintenance treatment arm on the survival outcomes was similar in the two age subgroups. Moreover, the safety profile of both induction and maintenance treatment, as well as the impact on QoL, was similar in elderly and younger patients, with no clinically meaningful or statistically significant differences.…”

<p>The impact of panitumumab treatment on survival and quality of life in patients with <em>RAS</em> wild-type metastatic colorectal cancer</p>

“…In the subgroup analysis of RAS WT patients from the PRIME study the combination of FOLFOX-4 and panitumumab showed a benefit over FOLFOX-4 in the subset of patients aged more than 65 years (n=188), in terms of OS (26.6 versus 17.4 months; HR 0.78; 95% CI, 0.58–1.09), PFS (9.7 versus 9.2 months; HR 0.88; 95% CI, 0.65–1.19) and ORR (49% versus 42%), without raising any safety concern 63. Positive results in terms of tolerability and efficacy were also recently reported in a retrospective study of 100 patients aged over 70 years (95.4% ECOG performance status 0–1) treated with doublet chemotherapy plus panitumumab, with a median PFS of 9.4 months (95% CI, 7.8–11.0) and a median OS of 23.0 months (95% CI, 20.6–25.3) 64…”

Treatment guidelines of metastatic colorectal cancer in older patients from the French Society of Geriatric Oncology (SoFOG)

“…Another sub-group post-hoc analysis of 110 patients over 65 years old treated in clinical trials with a combination of panitumumab and poly-chemotherapy was reported by the Hellenic group HORG. Response rate was 56.4% with a median PFS of 9.4 months and a median OS of 23.0 months [76]. Finally, the NCIC group analyzed cetuximab versus best supportive care (CO.17 study) or a combination of brivanib and cetuximab (CO.20 study) in patients with chemo-resistant disease.…”